Sparks - Basilea Pharmaceutica

More on this equity

Basilea’s (SIX: BSLN) milestone march continues

Basilea has reported another US$1.25m milestone payment for partner Pfizer, triggered by Cresemba sales in the region crossing a pre-defined threshold. This is the fourth milestone payment for Cresemba from the region this year and adds to the already strong H2 performance (c CHF33m/c US$38.5m milestone payments recorded in H224 so far; CHF35m in 2024 to date). The Asia-Pacific region, and in particular China (which accounts for c 20% of the market potential for Cresemba), is of key importance to Basilea, as the company approaches maturity in the US and European markets (market exclusivity until late 2027). Note that Cresemba has recorded in market sales of US$505m for the 12-months ended June 2024, a 20% y-o-y growth.

Next Sparks Commentary in this sector >

Latest

Consumer | Comment

16.10.24

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Equities

Equities by Sector

Sectors

Thematics

Latest

A net zero perspective – Investing in sustainability, technology & innovation

Banco Angolano de Investimentos (BAI) – Money-centre bank with lending optionality

The art of measurement – Challenges in metrology

Audiovisual

Latest

Protected: TEST

Deep dive into artificial intelligence interview: Northern Data Group

BB Biotech – executive interview

About Edison

About Edison

Careers

Sparks - Basilea Pharmaceutica

Latest

Games Workshop Group (GAW.L) – Second dividend of 85p per share

Henry Boot (LSE: BOOT) secures Manchester pre-let to Virgin Media O2

Marshalls (LSE: MSLH) sees improvement in Q3 versus H1

ADS-TEC Energy (Nasdaq: ADSE) – CFO Transition

Bellway (LSE: BWY) – FY24 down as expected but outlook encouraging

Subscribe to Edison